# ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial

> **NCT01913483** · PHASE3 · TERMINATED · sponsor: **The Medicines Company** · enrollment: 732 (actual)

## Conditions studied

- Peripheral Endovascular Interventions
- Bleeding

## Interventions

- **DRUG:** Bivalirudin
- **DRUG:** Unfractionated Heparin

## Key facts

- **NCT ID:** NCT01913483
- **Lead sponsor:** The Medicines Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-09-24
- **Primary completion:** 2016-03-16
- **Final completion:** 2016-03-16
- **Target enrollment:** 732 (ACTUAL)
- **Last updated:** 2017-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01913483

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01913483, "ENDOvascular Interventions With AngioMAX: The ENDOMAX Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01913483. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*